أغسطس 27, 2021 By mahmoud “A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer” Read More
أغسطس 24, 2021 By mahmoud A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131 Read More
أغسطس 24, 2021 By mahmoud De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results. Read More
أغسطس 24, 2021 By mahmoud “Breast Cancer Index (BCI) and Prediction of Benefit from Extended Aromatase Inhibitor (AI) Therapy (tx) in HR+ Breast Cancer: NRG Oncology/NSABP B-42. Trastuzumab Plus Endocrine Therapy or Chemotherapy as first-line Treatment for Metastatic Breast Cancer with Hormone Receptor-Positive and HER2-positive: The Sysucc-002 Randomized Clinical Trial. “ Read More
أغسطس 24, 2021 By mahmoud Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study. Read More